Under the same condition, the mice bearing MerTK-depleted tumours responded to BRAFi better than control mice bearing MerTK-expressing tumours after the treatment was stopped for 2 weeks (P1, day 60), but the response was lost after 4 weeks (P2, day 75) (Figure 6B), indicating that MerTK depletion at early time point potentially sensitized tumour response to vemurafenib in vivo. Here, MERTK is linked to neoplasm.